Hoffmann has been vice-chair of Roche since 2006 and a board director since 1996. Among many other roles, he is a trustee of ...

The developer is adding ancillary businesses that support the kind of high-profile companies that have been attracted to the ...

Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.

J.P. Morgan analyst Richard Vosser maintained a Sell rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

The Cytomegalovirus (CMV) Infection market growth is driven by factors like increase in the prevalence of Cytomegalovirus ...

Roche's Chugai Pharmaceutical is starting off its centennial year by spending some Swiss cheese. | Roche's Chugai Chugai ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...